^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    spevatamig (PT886)

    i
    Associations
    News

    Trials

    Company:
    Phanes Therap
    Drug class:
    CD47 inhibitor, CLDN18.2 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) (NCT05482893)
    Phase 1/2
    Phanes Therapeutics
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    03/15/2023
    Primary completion :
    12/01/2027
    Completion :
    04/01/2028
    CLDN18
    |
    HER-2 overexpression
    |
    Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • spevatamig (PT886)